Leukemia - Table of Contents alert Volume 27 Issue 4

Advertisement BD FACSCanto™ II: Timeless reliability. With its proven reliability and consistency, the BD FACSCanto™ II lets you keep work flowing so clinicians can more confidently deliver patient care. For over 40 years we've been making flow cytometry solutions that help make your job easier, your workflow more efficient, and your results more reliable. bdbiosciences.com/go/canto TABLE OF CONTENTS Volume 27, Issue 4 (April 2013) In this issue Editorials How to Manage… Reviews Original Articles Letters to the Editor Corrigendum Also new AOP Advertisement Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement Publish Your Paper in Leukemia With an Impact Factor of 9.561*, Leukemia is one of the most renowned journals in the field. Authors benefit from: • Competitive turnaround times • Respected editorial staff • High visibility and exposure through Nature.com • Open access option Visit the Author Page to submit your research. *2011 Journal Citation Reports® (Thomson Reuters, 2012)   Editorials Top Inimitable Imatinib: the range of targeted tumours expands to include T-cell lymphoma S D Turner on behalf of the European Research Initiative on ALCL Leukemia 2013 27: 759; 10.1038/leu.2012.304 Full Text Will the real myeloma please stand up? S Kumar and S V Rajkumar Leukemia 2013 27: 760-761; 10.1038/leu.2012.359 Full Text How to Manage… Top How to manage Waldenstrom’s macroglobulinemia Open C Buske and V Leblond Leukemia 2013 27: 762-772; advance online publication, February 6, 2013; 10.1038/leu.2013.36 Abstract | Full Text Reviews Top Parental imprinting regulates insulin-like growth factor signaling: a Rosetta Stone for understanding the biology of pluripotent stem cells, aging and cancerogenesis M Z Ratajczak, D-M Shin, G Schneider, J Ratajczak and M Kucia Leukemia 2013 27: 773-779; advance online publication, November 8, 2012; 10.1038/leu.2012.322 Abstract | Full Text Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group C Fernández de Larrea, R A Kyle, B G M Durie, H Ludwig, S Usmani, D H Vesole, R Hajek, J F San Miguel, O Sezer, P Sonneveld, S K Kumar, A Mahindra, R Comenzo, A Palumbo, A Mazumber, K C Anderson, P G Richardson, A Z Badros, J Caers, M Cavo, X LeLeu, M A Dimopoulos, C S Chim, R Schots, A Noeul, D Fantl, U-H Mellqvist, O Landgren, A Chanan-Khan, P Moreau, R Fonseca, G Merlini, J J Lahuerta, J Bladé, R Z Orlowski and J J Shah on behalf of the International Myeloma Working Group Leukemia 2013 27: 780-791; advance online publication, November 21, 2012; 10.1038/leu.2012.336 Abstract | Full Text SIAH proteins: critical roles in leukemogenesis O H Krämer, R H Stauber, G Bug, J Hartkamp and S K Knauer Leukemia 2013 27: 792-802; advance online publication, October 5, 2012; 10.1038/leu.2012.284 Abstract | Full Text Re-emergence of interferon-α in the treatment of chronic myeloid leukemia M Talpaz, R Hehlmann, A Quintás-Cardama, J Mercer and J Cortes Leukemia 2013 27: 803-812; advance online publication, November 7, 2012; 10.1038/leu.2012.313 Abstract | Full Text Original Articles Top MOLECULAR TARGETS FOR THERAPY Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l L Chen, A J Deshpande, D Banka, K M Bernt, S Dias, C Buske, E J Olhava, S R Daigle, V M Richon, R M Pollock and S A Armstrong Leukemia 2013 27: 813-822; advance online publication, November 9, 2012; 10.1038/leu.2012.327 Abstract | Full Text THERAPY Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis H Landau, H Hassoun, M A Rosenzweig, M Maurer, J Liu, C Flombaum, C Bello, E Hoover, E Riedel, S Giralt and R L Comenzo Leukemia 2013 27: 823-828; advance online publication, September 27, 2012; 10.1038/leu.2012.274 Abstract | Full Text Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced A Shimoni, N Shem-Tov, A Chetrit, Y Volchek, E Tallis, A Avigdor, S Sadetzki, R Yerushalmi and A Nagler Leukemia 2013 27: 829-835; advance online publication, October 17, 2012; 10.1038/leu.2012.299 Abstract | Full Text ACUTE LEUKEMIAS Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation Y Chen, H Kantarjian, S Pierce, S Faderl, S O'Brien, W Qiao, L Abruzzo, M de Lima, P Kebriaei, E Jabbour, N Daver, T Kadia, Z Estrov, G Garcia-Manero, J Cortes and F Ravandi Leukemia 2013 27: 836-842; advance online publication, November 8, 2012; 10.1038/leu.2012.319 Abstract | Full Text Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial A K Burnett, R K Hills, D Grimwade, J V Jovanovic, J Craig, M F McMullin, J Kell, K Wheatley, J A L Yin, A Hunter, D Milligan and N H Russell on behalf of the United Kingdom National Cancer Research Institute Acute Myeloid Leukaemia Subgroup Leukemia 2013 27: 843-851; advance online publication, December 10, 2012; 10.1038/leu.2012.360 Abstract | Full Text Cell of origin determines clinically relevant subtypes of MLL-rearranged AML A V Krivtsov, M E Figueroa, A U Sinha, M C Stubbs, Z Feng, P J M Valk, R Delwel, K Döhner, L Bullinger, A L Kung, A M Melnick and S A Armstrong Leukemia 2013 27: 852-860; advance online publication, December 13, 2012; 10.1038/leu.2012.363 Abstract | Full Text A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients Open E J Freireich, B Lichtiger, G Mattiuzzi, F Martinez, V Reddy and J Kyle Wathen Leukemia 2013 27: 861-865; advance online publication, October 17, 2012; 10.1038/leu.2012.301 Abstract | Full Text Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia C Bohnstedt, M Levinsen, S Rosthøj, B Zeller, M Taskinen, S Hafsteinsdottir, H Björgvinsdóttir, M Heyman and K Schmiegelow on behalf of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) Leukemia 2013 27: 866-870; advance online publication, November 9, 2012; 10.1038/leu.2012.325 Abstract | Full Text Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia A Mims, A R Walker, X Huang, J Sun, H Wang, R Santhanam, A M Dorrance, C Walker, P Hoellerbauer, S S Tarighat, K K Chan, R B Klisovic, D Perrotti, M A Caligiuri, J C Byrd, C-S Chen, L James Lee, S Jacob, K Mrózek, C D Bloomfield, W Blum, R Garzon, S Schwind and G Marcucci Leukemia 2013 27: 871-878; advance online publication, November 26, 2012; 10.1038/leu.2012.342 Abstract | Full Text MYELODYSPLASIAS Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia M van Gelder, L C de Wreede, J Schetelig, A van Biezen, L Volin, J Maertens, M Robin, E Petersen, T de Witte and N Kröger on behalf of the EBMT Chronic Malignancies Working Party Leukemia 2013 27: 879-888; advance online publication, October 16, 2012; 10.1038/leu.2012.297 Abstract | Full Text The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts M Nikpour, C Scharenberg, A Liu, S Conte, M Karimi, T Mortera-Blanco, V Giai, M Fernandez-Mercado, E Papaemmanuil, K Högstrand, M Jansson, I Vedin, J Stephen Wainscoat, P Campbell, M Cazzola, J Boultwood, A Grandien and E Hellström-Lindberg Leukemia 2013 27: 889-896; advance online publication, October 16, 2012; 10.1038/leu.2012.298 Abstract | Full Text Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency L Yang, A Mailloux, D E Rollison, J S Painter, J Maciejewski, R L Paquette, T P Loughran, K McGraw, H Makishima, R Radhakrishnan, S Wei, X Ren, R Komrokji, A F List and P K Epling-Burnette Leukemia 2013 27: 897-906; advance online publication, October 17, 2012; 10.1038/leu.2012.300 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance E Jabbour, P D le Coutre, J Cortes, F Giles, K N Bhalla, J Pinilla-Ibarz, R A Larson, N Gattermann, O G Ottmann, A Hochhaus, T P Hughes, G Saglio, J P Radich, D-W Kim, G Martinelli, J Reynolds, R C Woodman, M Baccarani and H M Kantarjian Leukemia 2013 27: 907-913; advance online publication, November 6, 2012; 10.1038/leu.2012.305 Abstract | Full Text Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy S Mustjoki, K Auvinen, A Kreutzman, P Rousselot, S Hernesniemi, T Melo, A-M Lahesmaa-Korpinen, S Hautaniemi, S Bouchet, M Molimard, R Smykla, F Y Lee, J Vakkila, S Jalkanen, M Salmi and K Porkka Leukemia 2013 27: 914-924; advance online publication, November 29, 2012; 10.1038/leu.2012.348 Abstract | Full Text CYTOGENETICS AND MOLECULAR GENETICS Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype A Rio-Machin, B I Ferreira, T Henry, G Gómez-López, X Agirre, S Alvarez, S Rodriguez-Perales, F Prosper, M J Calasanz, J Martínez, R Fonseca and J C Cigudosa Leukemia 2013 27: 925-931; advance online publication, October 22, 2012; 10.1038/leu.2012.302 Abstract | Full Text TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION A pathway from leukemogenic oncogenes and stem cell chemokines to RNA processing via THOC5 F Griaud, A Pierce, M B Gonzalez Sanchez, M Scott, S A Abraham, T L Holyoake, D D H Tran, T Tamura and A D Whetton Leukemia 2013 27: 932-940; advance online publication, October 3, 2012; 10.1038/leu.2012.283 Abstract | Full Text MYELOMA Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma J T Larsen, S K Kumar, A Dispenzieri, R A Kyle, J A Katzmann and S V Rajkumar Leukemia 2013 27: 941-946; advance online publication, October 16, 2012; 10.1038/leu.2012.296 Abstract | Full Text Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease E Kastritis, E Terpos, L Moulopoulos, M Spyropoulou-Vlachou, N Kanellias, E Eleftherakis-Papaiakovou, M Gkotzamanidou, M Migkou, M Gavriatopoulou, M Roussou, A Tasidou and M A Dimopoulos Leukemia 2013 27: 947-953; advance online publication, November 6, 2012; 10.1038/leu.2012.309 Abstract | Full Text Letters to the Editor Top ‘Stroke-like syndrome’ caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial J Bond, R Hough, J Moppett, A Vora, C Mitchell and N Goulden Leukemia 2013 27: 954-956; advance online publication, November 14, 2012; 10.1038/leu.2012.328 Full Text IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10) M K Westman, J Pedersen-Bjergaard, M T Andersen and M K Andersen Leukemia 2013 27: 957-959; advance online publication, November 29, 2012; 10.1038/leu.2012.347 Full Text A lack of positive effect of enhanced vegetative nervous system tonus on mobilization of hematopoietic stem and progenitor cells in patients suffering from acute psychotic syndromes J Kucharska-Mazur, D Pedziwiatr, A Poniewierska, M Tkacz, M Suszynska, M Tarnowski, J Samochowiec and M Z Ratajczak Leukemia 2013 27: 959-961; advance online publication, December 4, 2012; 10.1038/leu.2012.349 Full Text The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression A K Azab, E Weisberg, I Sahin, F Liu, R Awwad, F Azab, Q Liu, J D Griffin and I M Ghobrial Leukemia 2013 27: 961-964; advance online publication, December 5, 2012; 10.1038/leu.2012.353 Full Text Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells C Arndt, M von Bonin, M Cartellieri, A Feldmann, S Koristka, I Michalk, S Stamova, M Bornhäuser, M Schmitz, G Ehninger and M Bachmann Leukemia 2013 27: 964-967; advance online publication, January 17, 2013; 10.1038/leu.2013.18 Full Text Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia A A Lane, O Odejide, N Kopp, S Kim, A Yoda, R Erlich, N Wagle, G A Abel, S J Rodig, J H Antin and D M Weinstock Leukemia 2013 27: 968-971; advance online publication, February 1, 2013; 10.1038/leu.2013.30 Full Text Treatment patterns and outcomes in elderly patients with multiple myeloma S-M Bang, R A Kyle, S V Rajkumar and S Kumar Leukemia 2013 27: 971-974; advance online publication, September 5, 2012; 10.1038/leu.2012.259 Full Text Distinct patterns of gained chromosomes in high hyperdiploid acute lymphoblastic leukemia with t(1;19)(q23;p13), t(9;22)(q34;q22) or MLL rearrangements K Paulsson, C J Harrison, M K Andersen, L Chilton, A Nordgren, A V Moorman and B Johansson Leukemia 2013 27: 974-977; advance online publication, September 11, 2012; 10.1038/leu.2012.263 Full Text Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome L Sokol, L Cripe, H Kantarjian, M A Sekeres, S Parmar, P Greenberg, S L Goldberg, V Bhushan, J Shammo, R Hohl, A Verma, G Garcia-Manero, Y-P Li, A Lowe, J Zhu and A F List Leukemia 2013 27: 977-980; advance online publication, September 11, 2012; 10.1038/leu.2012.264 Abstract | Full Text High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24) Open F Micci, J Thorsen, I Panagopoulos, K B Nyquist, B Zeller, A Tierens and S Heim Leukemia 2013 27: 980-982; advance online publication, September 11, 2012; 10.1038/leu.2012.266 Full Text Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases M T Voso, E Fabiani, L Fianchi, G Falconi, M Criscuolo, R Santangelo, P Chiusolo, S Betti, F D'Alo', S Hohaus, V De Stefano and G Leone Leukemia 2013 27: 982-985; advance online publication, September 11, 2012; 10.1038/leu.2012.267 Full Text HLA-class II disparity is necessary for effective T cell mediated Graft-versus-Leukemia effects in NOD/scid mice engrafted with human acute lymphoblastic leukemia S Stevanović, M L J van Schie, M Griffioen and J H Falkenburg Leukemia 2013 27: 985-987; advance online publication, September 17, 2012; 10.1038/leu.2012.270 Full Text Successful double umbilical cord blood transplantation for relapsed juvenile myelomonocytic leukemia C Flotho, T Vraetz, P Lang, C M Niemeyer and B Strahm Leukemia 2013 27: 988-989; advance online publication, September 24, 2012; 10.1038/leu.2012.273 Full Text Uncovering early, lineage-dependent effects of TPMT genotype in adult acute lymphoblastic leukemia by minimal residual disease T Raff, M Kaiser, N Gökbuget, S Lüschen, M Ritgen, H Trautmann, R Reutzel, D Hoelzer, M Kneba and M Brüggemann Leukemia 2013 27: 989-992; advance online publication, September 27, 2012; 10.1038/leu.2012.275 Full Text PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5 G Fazio, V Cazzaniga, C Palmi, M Galbiati, M Giordan, G te Kronnie, A Rolink, A Biondi and G Cazzaniga Leukemia 2013 27: 992-995; advance online publication, October 1, 2012; 10.1038/leu.2012.281 Full Text Corrigendum Top Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients H Ludwig, D Milosavljevic, N Zojer, J M Faint, A R Bradwell, W Hübl and S J Harding Leukemia 2013 27: 996; 10.1038/leu.2013.25 Full Text Advertisement Register for the Bone Marrow Transplantation e-alert and never miss an article. With an Impact Factor of 3.746* and ranked #6 in Transplantation, BMT is one of the most highly regarded journals in the field. Join 50,000 of your colleagues who receive the BMT monthly e-alert - SIGN UP to stay up-to-date in the latest research. *2011 Journal Citation Reports® (Thomson Reuters, 2012)   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.